Do you perform quality checks on finished products?

Yes, we conduct 100% inspection including visual and functional checks on all finished products.

What payment methods do you accept?

We accept LC, T/T, D/P, PayPal, Western Union, and small-amount payments.

Tba-Fx8

Name: Toshiba Maxpia C Cleaning Solution for Biochemical Analyzer Accute Tba120/ Tba2000 /Tba-Fx8
Brand: Zhejiang Xinke Medical Technology Co., Ltd.
SKU: 2204852055

Zhejiang, ChinaZhejiang Xinke Medical Technology Co., Ltd.

US$1.00

1 Piece

Sample price:US$1.00/piece.Request sample

Product profile

Customization

Available

Type

IVD Reagent

Application

Human

Model NO.

JXK-121

Certificate

CE ISO9001 ISO13485

Model

Tba120/ Tba2000 /Tba-Fx8

Product Name

Maxpia C

Transport Package

Carton

Specification

500ml

Trademark

Xinke

Origin

China

Key features

Wide Compatibility: Compatible with Accute Tba120, Tba2000, and Tba-Fx8 biochemical analyzers.

Flexible Customization: Offers flexible customization options to meet specific laboratory needs.

Certified Quality: Holds CE, ISO9001, and ISO13485 certifications for medical device standards.

Manufacturer Direct: Sold directly by a manufacturer with 20 years of export experience.

100% Quality Inspection: Every finished product undergoes visual and functional inspection before shipping.

Fast Lead Time: Production completed within 15 working days for both peak and off-peak seasons.

Low MOQ: Minimum order quantity is just 1 piece, suitable for small labs.

Company profile

Importers and ExportersYears of Export Experience

Zhejiang Xinke Medical Technology Co., Ltd.

Zhejiang, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: OEM Service Available CertifiedCustomization Options: Flexible customization CertifiedExport Year: 20 Years CertifiedNearest Port: Ningbo PortAverage Response Time: ≤2.79h

AI-Powered supplier vetting

SummaryThe supplier operates in the clinical in vitro diagnostic reagent field and reports ten years of ISO9001 and ISO13485 quality-system certification. It offers flexible customization, has OEM experience with well-known brands, possesses self-managed import/export rights, and has exported for 20 years, with exports representing 51%–70% of total sales. Quality inspection procedures are documented and consistently followed, while stated lead times are within 15 working days in both peak and off-season. However, the supplier reports no inventory, overseas warehouse, overseas showroom, overseas agents or branches, offline trade-show participation, ODM service, SDK, recent new-product development, ERP, OA, CRM, SAP, or broader digitalization initiatives. Financial information is inconsistent or insufficiently interpretable in the provided records, so financial credibility cannot be determined.

Supplier typeThe supplier identifies itself as a company in the clinical in vitro diagnostic reagent field and has self-managed import/export rights with 20 years of export experience. This supports classification as an export-capable manufacturer or supplier in the medical in vitro diagnostics sector.

CertificationsThe company states that it has maintained ISO9001 and ISO13485 quality-system certifications for ten years. These explicitly documented certifications support a positive assessment of its quality-system credentials.

R&D capabilityThe supplier reports no new products in the past year, no ODM service, no available SDK, and no current enterprise digitalization or technical-transformation plan. These explicit limitations indicate weak demonstrated innovation capability.

Customization capabilityThe supplier explicitly provides flexible customization through both its R&D and design-service capabilities. This directly supports a positive assessment of customization capability, although ODM service is not offered.

Client casesThe supplier states that it provides OEM services for well-known brands, which is evidence of relevant customer experience. No specific brand names, project details, or verifiable case descriptions are provided, so the evidence is positive but limited.